Why First-Line Nivolumab Is No Better Than Chemo

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nd2017-004
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy